Cargando…

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab

Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. Materials and methods: Sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishino, Mizuki, Cryer, Sarah K., Okajima, Yuka, Sholl, Lynette M., Hatabu, Hiroto, Rabin, Michael S., Jackman, David M., Johnson, Bruce E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: e-Med 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392782/
https://www.ncbi.nlm.nih.gov/pubmed/22743083
http://dx.doi.org/10.1102/1470-7330.2012.0027
_version_ 1782237644245172224
author Nishino, Mizuki
Cryer, Sarah K.
Okajima, Yuka
Sholl, Lynette M.
Hatabu, Hiroto
Rabin, Michael S.
Jackman, David M.
Johnson, Bruce E.
author_facet Nishino, Mizuki
Cryer, Sarah K.
Okajima, Yuka
Sholl, Lynette M.
Hatabu, Hiroto
Rabin, Michael S.
Jackman, David M.
Johnson, Bruce E.
author_sort Nishino, Mizuki
collection PubMed
description Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. Materials and methods: Seventy-two patients with NSCLC treated with bevacizumab therapy were identified retrospectively. Baseline and follow-up chest computed tomography scan were reviewed to identify tumoral cavitation and subsequent filling in of cavitation. Radiographic cavitation patterns were classified into 3 groups. The clinical and outcome data were correlated with cavity formation and patterns. Results: Out of 72 patients, 14 patients developed cavitation after the initiation of bevacizumab therapy (19%; median time to event, 1.5 months; range 1.0–24.8 months). Three radiographic patterns of tumoral cavitation were noted: (1) development of cavity within the dominant lung tumor (n = 8); (2) development of non-dominant cavitary nodules (n = 3); and (3) development of non-dominant cavitary nodules with adjacent interstitial abnormalities (n = 3). Eleven patients (79%) demonstrated subsequent filling in of cavitation (the time from the cavity formation to filling in; median 3.7 months; range 1.9–22.7 months). No significant difference was observed in the clinical characteristics, including smoking history, or in the survival between patients who developed cavitation and those who did not. Smoking history demonstrated a significant difference across 3 radiographic cavitation patterns (P = 0.006). Hemoptysis was noted in 1 patient with cavity formation and 4 patients without, with no significant difference between the 2 groups. Conclusion: Tumoral cavitation occurred in 19% in patients with NSCLC treated with bevacizumab and demonstrated 3 radiographic patterns. Subsequent filling in of cavitation was noted in the majority of cases.
format Online
Article
Text
id pubmed-3392782
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher e-Med
record_format MEDLINE/PubMed
spelling pubmed-33927822012-07-18 Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab Nishino, Mizuki Cryer, Sarah K. Okajima, Yuka Sholl, Lynette M. Hatabu, Hiroto Rabin, Michael S. Jackman, David M. Johnson, Bruce E. Cancer Imaging Original Article Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. Materials and methods: Seventy-two patients with NSCLC treated with bevacizumab therapy were identified retrospectively. Baseline and follow-up chest computed tomography scan were reviewed to identify tumoral cavitation and subsequent filling in of cavitation. Radiographic cavitation patterns were classified into 3 groups. The clinical and outcome data were correlated with cavity formation and patterns. Results: Out of 72 patients, 14 patients developed cavitation after the initiation of bevacizumab therapy (19%; median time to event, 1.5 months; range 1.0–24.8 months). Three radiographic patterns of tumoral cavitation were noted: (1) development of cavity within the dominant lung tumor (n = 8); (2) development of non-dominant cavitary nodules (n = 3); and (3) development of non-dominant cavitary nodules with adjacent interstitial abnormalities (n = 3). Eleven patients (79%) demonstrated subsequent filling in of cavitation (the time from the cavity formation to filling in; median 3.7 months; range 1.9–22.7 months). No significant difference was observed in the clinical characteristics, including smoking history, or in the survival between patients who developed cavitation and those who did not. Smoking history demonstrated a significant difference across 3 radiographic cavitation patterns (P = 0.006). Hemoptysis was noted in 1 patient with cavity formation and 4 patients without, with no significant difference between the 2 groups. Conclusion: Tumoral cavitation occurred in 19% in patients with NSCLC treated with bevacizumab and demonstrated 3 radiographic patterns. Subsequent filling in of cavitation was noted in the majority of cases. e-Med 2012-05-25 /pmc/articles/PMC3392782/ /pubmed/22743083 http://dx.doi.org/10.1102/1470-7330.2012.0027 Text en © 2012 International Cancer Imaging Society
spellingShingle Original Article
Nishino, Mizuki
Cryer, Sarah K.
Okajima, Yuka
Sholl, Lynette M.
Hatabu, Hiroto
Rabin, Michael S.
Jackman, David M.
Johnson, Bruce E.
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
title Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
title_full Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
title_fullStr Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
title_full_unstemmed Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
title_short Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
title_sort tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392782/
https://www.ncbi.nlm.nih.gov/pubmed/22743083
http://dx.doi.org/10.1102/1470-7330.2012.0027
work_keys_str_mv AT nishinomizuki tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab
AT cryersarahk tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab
AT okajimayuka tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab
AT sholllynettem tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab
AT hatabuhiroto tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab
AT rabinmichaels tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab
AT jackmandavidm tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab
AT johnsonbrucee tumoralcavitationinpatientswithnonsmallcelllungcancertreatedwithantiangiogenictherapyusingbevacizumab